New hope to shield transplant patients from dangerous immune attack
NCT ID NCT07440654
Summary
This study is testing whether adding a new drug called gecacitinib to standard treatment can better prevent a dangerous immune reaction called acute Graft-Versus-Host Disease (aGVHD) in patients with myelofibrosis. It will involve 40 adults with advanced myelofibrosis who are receiving a stem cell transplant from a donor. The main goal is to see if this combination lowers the rate of severe aGVHD, which can damage organs and be life-threatening.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGVHD PROPHYLAXIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.